EMVision Brings Portable Stroke Scanner Into Real-World Roadside Use

First Roadside Study Clears Usability Milestone

EMVision Medical Devices Limited (ASX:EMV) has successfully taken its First Responder brain scanner beyond the hospital and into real-world roadside settings, completing Stage 1 of a feasibility study with Melbourne’s Mobile Stroke Unit. The result is an operational milestone rather than a diagnostic breakthrough: the single-site study involved only 10 participants and was explicitly designed to assess usability and workflow, not clinical accuracy.

Participants were scanned at six residences, three ambulances and one workplace, including people on stretchers, beds, couches and the ground. The mean scan time was 6.7 minutes, with scenes located 3 to 18 kilometres by road from the Royal Melbourne Hospital. No device-related adverse events were reported.

Operators rated scanner operation as easy in 100% of responses. Preparation, head-size assessment, start-up and tablet connection also received positive feedback, while securing the device inside the Mobile Stroke Unit was rated positively in 90% of cases and packing and preparation in 80%. The main improvement areas involved moving and loading the scanner, giving EMVision a defined list of engineering priorities.

Lighter Production Units Target 2027 Studies

EMVision says the Stage 1 findings are being incorporated into production-equivalent First Responder units that will contain fewer components and weigh less than the prototypes used in the field. The company says the next-generation units are being designed to improve on the diagnostic performance of its emu™ scanner, although this announcement provides no diagnostic data for the First Responder device.

The company expects those units to be ready in the first half of calendar 2027. Their availability would allow Stage 2 of the Mobile Stroke Unit study to begin, with paired First Responder and standard-of-care CT data collected from patients suspected of acute stroke. That stage is intended to support algorithm development and later validation, including a demonstration of performance equal to or better than emu™ for the purposes of substantial equivalence.

Grant Payment Adds Non-Dilutive Funding

EMVision also received a $650,437 progress payment under its Industry Growth Program grant. The Australian Government awarded the company a $5 million grant in June 2025 to support development and commercialisation of the First Responder scanner, with $2.2 million still due over the life of the program.

Stroke Alliance MoU Opens Funding Route

A two-year, non-binding and non-exclusive memorandum of understanding with Australian Stroke Alliance adds a second funding angle. The parties intend to pursue non-dilutive research and translational funding for pre-hospital stroke diagnosis, building on their work under the $40 million MRFF Stage 2 “golden hour” program, through which EMVision says it has received $8 million.

The arrangement brings together ASA’s clinical networks and ambulance partners with EMVision’s technology platform, but it is not a funding commitment. Neither party is obliged to submit a particular application, either can terminate the MoU on 30 days’ notice, and competitive grant outcomes remain uncertain.

The immediate evidence is therefore operational: a compact scanner was used in varied emergency environments, quickly and without reported device-related adverse events. The more consequential test lies ahead, when production-equivalent units must generate paired diagnostic data and clear the clinical and regulatory hurdles separating field feasibility from market access.